SRC and thyroid gland carcinoma: Accordingly, our previous studies have demonstrated that, in BRAF- and RAS-mutant thyroid cancer cells, combined Src and MEK1/2 inhibition synergistically inhibits growth in vitro and in vivo through the induction of apoptosis; however, these effects were not achieved in PIK3CA-mutant thyroid cancer cells [11,12].